Navigation Links
New hope for hepatitis C sufferers
Date:2/7/2008

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers.

University of Adelaide virologists Dr Michael Beard and Dr Karla Helbig will work with colleagues from the University of NSW to develop new strategies to treat and prevent hepatitis C, which infects more than 170 million people around the world.

The scientists, who are also attached to the Institute of Medical and Veterinary Science and Royal Adelaide Hospital, hope to identify antiviral proteins that can be used in the fight against hepatitis C.

Currently there is no effective vaccine and the existing treatment is expensive and often causes severe side effects. The success rate also varies between 50-80% so many sufferers cannot be helped by current approaches.

The funds, awarded by the National Health and Medical Research Council (NHMRC), are part of a larger $17.7 million joint program grant, tackling both HIV/AIDS and hepatitis C and involving nine scientists from across Australia.

Dr Beard said this was the first Australian program grant awarded to study both HIV/AIDS and HCV/hepatitis C.

The development of vaccines and better treatments for both these viruses are urgent global health priorities, Dr Beard said. This program brings together a team of researchers with skills in basic virology and immunology with experts who can translate laboratory findings into human clinical trials.

This latest grant is an adjunct to three NHMRC project grants awarded to Dr Beards team in the past two years specifically for hepatitis C research.

In 2006 the virologist was awarded more than $894,000 to investigate the link between alcohol and hepatitis C, and the basic mechanisms of liver disease.

In Australia, more than 264,000 people have been infected with the hepatitis C virus and there are approximately 10,000 new infections per year. A proportion of these are intravenous drug users, with alcohol playing a significant role in disease progression, Dr Beard said.

He said vaccines had been trialled for HIV, but with little success. There is antiretroviral treatment but this does not eradicate HIV, it only keeps it under control for a period of time. It is also very expensive and therefore not accessible on a global scale.

Dr Beard said the program would provide a pipeline to develop and test vaccines and novel treatments in a timely fashion.


'/>"/>

Contact: Michael Beard
michael.beard@adelaide.edu.au
61-883-035-522
University of Adelaide
Source:Eurekalert  

Related biology news :

1. Clearance of hepatitis C viral infection after liver transplantation
2. Who will recover spontaneously from hepatitis C virus infection
3. Possible hepatitis C vaccine
4. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
5. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
6. New Swedish research hope for millions of sufferers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New hope for hepatitis C sufferers
(Date:12/15/2016)... Germany , December 15, 2016 ... provider, today announced an agreement with NuData Security, an ... forces. The partnership will enable clients to focus on good ... local data protection regulation. ... In order to provide a one-stop fraud ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported ... to over 40 granted and pending patents. ... , The Company,s IP portfolio ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... hardware components needed to estimate the force and pressure applied to touch ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... organization with services spanning the full spectrum of drug and device development, and ... services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a leading ... PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB ... sized form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB ...
(Date:1/18/2017)... ... 2017 , ... Executive search firm Slone Partners proudly supports ... the advancement of the clinical trials segment. Hosted in Miami, this conference brings ... and management. , As executive talent specialists in the industries central to ...
Breaking Biology Technology: